The EU and US are using substandard medicines as an excuse to tighten IP rules, boosting pharma profits while making it harder for the poor to access drugs, according to Oxfam.
AstraZeneca has started construction a €30 million tablet
manufacturing plant in Egypt that could form a springboard for an
expansion into emerging markets.
An expert group on intellectual property rights (IPRs) has warned
that rules governing the protection of copyrights, database rights
and patents hamper scientific endeavour and must be changed 'in the
interest of society',...